SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer

SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07535632 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 58 participants, started 2026-06-01 and due to reach its primary completion in 2028-06-01. Interventions recorded: SBRT; Sintilimab; Bevacizumab; Trifluridine and Tipiracil Tablets; Standard of Care (Investigator Selected). Conditions listed: Colorectal Neoplasms. Primary outcome: Progression-Free Survival (PFS). Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed colorectal cancer with unresectable metastatic or recurrent lesions". Sites: China. No results are recorded here; the registry entry is the source.